

**CONCLUSION:**

Long term therapy decision for hormone positive breast cancer patients is complex as every tumor has different nucleic acid expression. Under treatment and over treatment both are equally no appropriate in patient management. The score provides clinicians with a single-digit number predicting the proliferation risk of sample cancer cells to guide diagnosis and adjuvant (post-surgery) chemotherapy decision-making. Personalized recurrent risk score focus on the modality of treatment with different combination of drugs thus benefit patient improvising quality of life. Digistain provides a more affordable solution that allows for borderline low/ medium risk patients to benefit from a prognostic test.

**REFERENCE:**

1. Charles Coombes et al. Validation of a novel and rapid reagent free assay to predict outcomes for adjuvant therapy decision making in hormone receptor-positive breast cancer. JCO 41, 545-545(2023).DOI:10.1200/JCO.2023.41.16\_suppl.545
2. Coombes, R.C., Angelou, C., Al-Khalili, Z. et al. Performance of a novel spectroscopy-based tool for adjuvant therapy decision-making in hormone receptor-positive breast cancer: a validation study. Breast Cancer Res Treat 205, 349–358 (2024).